Efficacy of 3% hypertonic saline nebulization in children hospitalized with moderate bronchiolitis


  • Rajkumar C. Radhakrishnan Department of Pediatrics, Gleneagles Global Hospital, Perumbakkam, Chennai, Tamil Nadu, India
  • Ramkumar A. Padmanabhan Department of Pediatrics,Institute of Child Health, Madras Medical College, Chennai, Tamil Nadu, India




Moderate bronchiolitis 3% saline, Nebulization cough and wheeze resolution time


Background: Bronchiolitis is one of the most common lower respiratory tract viral infections within the first 2 years of life; more than one third of children develop bronchiolitis. Of these, 1 out of 10 children will be hospitalized.

Methods: We did interventional, randomized control study of 3% hypertonic saline nebulization to 100 moderate bronchiolitis children admitted during our study period of 18 months. Primary outcome of duration of hospital stay and secondary outcome of Cough resolution time, wheeze resolution time are analyzed. No side effects or adverse drug reactions are observed.

Results: There was a 3.9 percentage reduction in length of stay in the hypertonic saline group compared to the control group which received supportive therapy alone. But these findings were not statistically significant. The cough resolution time and the wheeze resolution time were statistically significant shorter duration in the study group than the control group.

Conclusions: Nebulized hypertonic saline significantly reduced the cough and wheeze resolution time but not significantly reduced the hospital stay.


American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118:1774-93.

Clinical Practice Guideline. The diagnosis, management, and prevention of bronchiolitis. American Academy of Pediatrics. 2014;134 (5):e1474-e1502.

Hanson IC, Shearer WT. Bronchiolitis. In: McMillan JA, Feigin RD, DeAngelis C, Jones MD, eds. Oski’s Pediatrics: Principles and Practice, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006:1391.

Schroeder AR, Mansbach JM. Recent evidence on the management of bronchiolitis. Curr Opin Pediatr. 2014 Jun;26(3):328.

Al-Ansari K, Sakran M, Davidson BL, El Sayyed R, Mahjoub H, Ibrahim K. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. J Pediatr. 2010 Oct;157(4):630-4.

Øymar K, Skjerven HO, Mikalsen IB. Acute bronchiolitis in infants, a review. Scandinavian J Trauma, Resusc Emerg Med. 2014 Dec;22(1):23.

Shann F. WHO definition of tachypnoea in children. Lancet. 1992 Jan 18;339(8786):176-7.

NICE guideline. Bronchiolitis in children: diagnosis and management. Available at https://www.nice.org.uk/guidance/ng9.

John TJ, Cherian T, Steinhoff MC, Simoes EA, John M. Etiology of acute respiratory infections in children in tropical southern India. Rev Infect Dis. 1991 May 1;13(Supplement_6):S463-9.

Mandelberg A, Tal G, Witzling M, Someck E, Houri S, Balin A et al. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest. 2003 Feb 1;123(2):481-7.

Tal G, Cesar K, Oron A, Houri S, Ballin A, Mandelberg A. Hypertonic saline/epinephrine treatment in hospitalized infants with viral bronchiolitis reduces hospitalization stay: 2 years experience. IMAJ-RAMAT GAN. 2006 Mar 1;8(3):169.

Kuzik BA, Al Qadhi SA, Kent S, Flavin MP, Hopman W, Hotte S et al. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr. 2007 Sep 1;151(3):266-70.






Original Research Articles